Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 6/20 | 0.66 |
| ▸ | KLK7 | P49862 | 1/20 | 0.65 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.65 |
| ▸ | PREP | P48147 | 3/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16272917 | 1.00 | FKBP1A (0.66) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL5405520 | 0.92 | FKBP1A (0.61) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL2217494 | 0.92 | FKBP1A (0.61) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL13742997 | 0.92 | FKBP1A (0.61) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL5405516 | 0.92 | FKBP1A (0.61) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL2217493 | 0.92 | FKBP1A (0.61) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL847403 | 0.92 | TSHR (0.64) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL13742619 | 0.92 | FKBP1A (0.61) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL14893288 | 0.92 | TSHR (0.64) | FKBP1AKLK7KLK5PREPCTRB1 | |
| SCHEMBL631581 | 0.92 | FKBP1A (0.58) | FKBP1AKLK7KLK5PREPCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746440-B1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | UNIV TEXAS (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3746440-B1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | UNIV TEXAS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11345659-B2 | Pipecolic esters for inhibition of the proteasome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345659-B2 | Pipecolic esters for inhibition of the proteasome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210002220-A1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2021-01-07 | — | — | US | disclosed |
| WO-2019152527-A1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-08 | — | — | WO | disclosed |
| US-9512074-B2 | Radiolabeled inhibitors of the amino acid transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150056138-A1 | Radiolabeled Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA | 2015-02-26 | — | — | US | disclosed |
| US-8895607-B2 | Inhibitors of the amino acid transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2014002058-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20130065935-A1 | Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | THE UNIVERSITY OF MONTANA | 2013-03-14 | — | — | US | disclosed |
| EP-0279750-B1 | AMINOACID DERIVATIVES AS ANTIHYPERTENSIVES | Asahi Breweries, Ltd. (JP) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065935-A1 | Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | SLC1A2, SLC1A1, SLC1A3 | FKBP1A 3599/4885KLK7 4069/4885KLK5 4306/4885 |
| US-20150056138-A1 | Radiolabeled Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 | SLC1A2, SLC1A1, SLC1A3 | FKBP1A 3208/4885KLK7 3713/4885KLK5 4018/4885 |
| US-11345659-B2 | Pipecolic esters for inhibition of the proteasome | PSMG3, PSME3, PSMC1 | FKBP1A 1719/4885KLK7 3957/4885KLK5 4090/4885 |
| US-20210002220-A1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | PSMG3, PSME3, PSMC1 | FKBP1A 1719/4885KLK7 3957/4885KLK5 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.